The ability to rationally or randomly modify proteins has expanded their employment in various bioanalytical applications. The bioluminescent protein, aequorin, has been employed as a reporter for decades due to its simplistic, non-hazardous nature and its high sensitivity of detection. More recently aequorin has been subject to spectral tuning. Techniques such as random and site-directed mutagenesis, the incorporation of coelenterazine analogues and the incorporation of non-natural amino acids have expanded the palette of aequorin by altering their emission wavelengths and/or half-lifes. Due to the increased diversity of aequorin, it can be used in multianalyte detection. Although aequorin has been studied extensively and has been used as a reporter in a wide array of applications, it has never been employed as a reporter in systems that involve the splitting of aequorin. Herein we describe the splitting of aequorin in such a way where it becomes the reporter protein in the development of protein-based molecular switches. We have created two distinct protein switches by genetically inserting the glucose-binding protein and the sulfate-binding protein into the aequorin sequence, splitting it in such a manner that it allows for the selective detection of glucose and sulfate, respectively. In a separate investigation, we developed a bioluminescence inhibition binding assay for the detection of hydroxylated polychlorinated biphenyls. These systems have shown that they can be employed in the detection of the respective analyte in biological as well as in environmental samples, which demonstrated a sensitive, fast alternative approach to current methods for on-site screening. Furthermore, we propose the rational design, preparation and use of truncated aequorin fragments in bioanalytical platforms such as multi-analyte detection, protein complementation assays and protein tagging assays based on our discovery that truncated aequorin retains partial bioluminescence emission. One such truncated aequorin demonstrated a large red shift in the emission maximum. It is envisioned that this new red-shifted truncated aequorin will find applications in multi-analyte detection. We anticipate that this work will lead to the discovery of additional functional truncated aequorin fragments that can be employed in novel protein-protein interactions or protein folding systems.

A descoberta de inibidores seletivos é extremamente importante para o desenvolvimento de novos fármacos que possam ser usados no tratamento de pacientes diagnosticados com a doença de Alzheimer (DA). Neste contexto, o desenvolvimento de métodos de triagem para a identificação de novos compostos biologicamente ativos se torna interessante. Butirilcolinesterase (BChE, EC 3.1.1.8) é uma serina hidroxilase que está classicamente associada à hidrólise do neurotransmissor acetilcolina (ACh) formando colina e ácido acético. Este trabalho descreve a imobilização covalente da BChE de soro humano nas paredes internas de capilares de sílica fundida utilizando o agente espaçador glutaraldeído, e sua aplicação na triagem de inibidores seletivos. O ICER-BChE resultante foi conectado a um sistema de cromatografia líquida de alta eficiência com monitoramento on line da atividade catalítica, envolvendo detecção UV. Após os estudos das melhores condições cromatográficas, variações de pH e vazão e a influência de solventes orgânicos na atividade enzimática o método foi validado com o uso de inibidores padrões. O maior valor obtido com o ICER-BChE no parâmetro cinético, constante de Michaelis KM = 33,6 ± 6,9 mM, comparado com a enzima em solução, KM = 0,12 ± 0,02 mM, evidencia o efeito da imobilização sobre a afinidade pelo substrato. No entanto, houve retenção da atividade catalítica e seletividade frente a inibidores padrão. O método foi aplicado na triagem de novos ligantes utilizando cinco coleções de diferentes classes de compostos, entre derivados cumarínicos, complexos metálicos com cobre (Cu), complexos metálicos com cobalto (Co) e zinco (Zn), glicosídeos, e derivados de fenilpropanóides e ácido barbitúrico. Desta triagem foram selecionados sete compostos promissores com os quais foram realizados os estudos sobre a potência mínima inibitória (IC50) e destes quatro foram escolhidos para estudos de mecanismos de ação utilizando o ICER-BChE. Dos complexos metálicos os melhores compostos foram o HPTBCu (IC50 = 8,74 ± 1,5 µM, Ki = 9,6 ± 0,5 M), o NarBCu (IC50 = 8,0 ± 1,4 µM, Ki = 2,0 ± 0,1 M) ambos com mecanismo competitivo o HesFCu (IC50 = 13,6 ± 2,9 µM), o NNINABCu (IC50 = 94,8 ± 16) e o NarFCu (IC50 = 81,7 ± 13). Dos derivados cumarínicos os compostos 17 (IC50 =109 ± 21 µM, Ki = 108 ± 10 M) e 19 (IC50 =128 ± 28 µM, Ki =36.0 ± 5.0 M) apresentaram mecanismo incompetitivo. Os resultados demonstraram que a abordagem proposta é útil na triagem on line de inibidores seletivos, pois fornece resultados rápidos, precisos e reprodutíveis. / The discovery of selective inhibitors is extremely important for the development of drugs that can be used in the treatment of patients diagnosed with the Alzheimer disease (AD). In this context, the development of screening methods for the identification of new, biologically active compounds is a challenging task. Butyrylcholinesterase (BChE, EC 3.1.1.8) is a serine hydroxylase that is classically associated with the hydrolysis of the neurotransmitter acetylcholine (ACh), which yields choline and acetic acid. This paper describes the development of capillary enzyme reactors (ICERs) containing BChE from the human serum, covalently immobilized onto silica fused capillaries, using glutaraldehyde as spacer, and its application in the screening of selective inhibitors. The resulting BChE-ICER was connected to a liquid chromatography system high efficiency where monitoring of activity was online involving UV detection. After studying the best chromatographic conditions, pH variations, flow-rate and the influence of organic solvents on enzyme activity method was validated using standard inhibitors. The higher value obtained with the BChE-ICER in kinetic parameter, constant Michaelis KM = 33.6 ± 6.9 mM, compared with the enzyme in solution, KM = 0.12 ± 0.02 mM, shows the effect of immobilized on the affinity substrate. However, there was retention of catalytic activity and selectivity towards standard inhibitors. The method was applied in the screening of new ligands using collections of five different compounds, among coumarin derivatives, metal complexes with copper (Cu) metal complexes with cobalt (Co) and zinc (Zn), glycosides, phenylpropanoids and derivatives, and barbituric acid. These screenings were selected seven promising compounds with which the studies were made on the minimum inhibitory potency (IC50) and these four were chosen for studies of mechanisms of action using the ICER-BChE. Of the compounds metal complexes best were HPTBCu (IC50 = 8,74 ± 1,5 µM, Ki = 9,6 ± 0,5 M), NarBCu (IC50 = 8,0 ± 1,4 µM, Ki = 2,0 ± 0,1 M) both competitive mechanism, the HesFCu (IC50 = 13.6 ± 2.9 µM), NNINABCu (IC50 = 94.8 ± 16 µM) and NarFCu (IC50 = 81.7 ± 13 µM). Of coumarin derivatives, 17 (IC50 =109 ± 21 µM, Ki = 108 ± 10 M) and 19 (IC50 =128 ± 28 µM, Ki =36.0 ± 5.0 M) showed mechanism uncompetitive. The results demonstrated that the proposed approach is useful in screening for selective inhibitors online because it provides quick results, accurate and reproducible.

PhD (Microbiology) / Department of Microbiology / High genetic diversity is a major contributory factor in the development of drug resistance, in addition to challenges in diagnosis and treatment monitoring in the therapeutics of human immunodeficiency virus (HIV) .Within the wide HIV-1 diversity, differences in mutational frequency, disease progression, drug response and transmission amongst HIV-1 subtypes have been shown. In spite HIV-1 subtype C (HIV-1C) being the most prevalent variant globally, none of the available drugs nor screening assays for inhibitory molecules have been developed targeting the genetics of this important subtype. This study therefore aimed to overexpress and biophysically characterize HIV-1C reverse transcriptase and protease to serve as reagents in the development of assays for routine screening of molecules inhibitory to HIV-1C. Heterologous expression of HIV-1C reverse transcriptase and protease isolates that are prevalent in South Africa was carried out in Escherichia coli (E. coli (BL21-DE3). The secondary and tertiary structures of the proteins were determined using, circular dichroism (CD) and fluorescence spectroscopy respectively. Thereafter, interaction studies to delineate interaction properties of natural products for possible inhibition of protease were conducted. Furthermore, in silico studies to determine binding interactions, further confirmed by in vitro binding assays of a pepsin inhibitor homolog (Bm-33) from Brugia malayi , against protease were also conducted. Expressed reverse transcriptase and protease from the globally prevalent HIV-1C were shown to be structurally and functionally intact for application in downstream HIV-1 inhibition assays. Interaction studies on the other hand revealed successful inhibition of the expressed HIV-1C PR with gallotanin. Furthermore, binding interactions of Bm-33 and HIV-1 PR revealed the first intermolecular interactions of the two molecules displaying possible inhibition of HIV-1 PR / NRF